David Shaw’s Nurix Therapeutics NRIX Stock Holding History

David Shaw’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.48M	Sell	184,551 -159,652	-46%	-$2.72M	﹤0.01%	2495
2026 Q1	$5.34M	Buy	+344,203	New	+$5.71M	﹤0.01%	2123
2025 Q2	–	Sell	-59,923	Closed	-$712K	–	4600
2025 Q1	$712K	Sell	59,923 -52,918	-47%	-$885K	﹤0.01%	3295
2024 Q4	$2.13M	Buy	112,841 +40,001	+55%	+$917K	﹤0.01%	2678
2024 Q3	$1.64M	Buy	+72,840	New	+$1.65M	﹤0.01%	2873
2023 Q4	–	Sell	-25,358	Closed	-$199K	–	4503
2023 Q3	$199K	Sell	25,358 -26,144	-51%	-$239K	﹤0.01%	3767
2023 Q2	$515K	Sell	51,502 -7,535	-13%	-$76.8K	﹤0.01%	3416
2023 Q1	$524K	Sell	59,037 -32,672	-36%	-$340K	﹤0.01%	3530
2022 Q4	$1.01M	Buy	91,709 +31,695	+53%	+$382K	﹤0.01%	3450
2022 Q3	$782K	Buy	+60,014	New	+$950K	﹤0.01%	3765
2021 Q3	–	Sell	-24,012	Closed	-$637K	–	5137
2021 Q2	$637K	Sell	24,012 -17,186	-42%	-$505K	﹤0.01%	3895
2021 Q1	$1.28M	Buy	+41,198	New	+$1.56M	﹤0.01%	2910

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

David Shaw's NRIX Position: Q2 2026 in Review

David Shaw reduced its Nurix Therapeutics (NRIX) stake by 46% in Q2 2026, selling an estimated $2.72M and leaving 184,551 shares worth $4.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2495.

David Shaw first reported a position in NRIX in Q1 2021 and has held it in 12 quarters since. The position peaked at $5.34M in Q1 2026. 210 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

David Shaw held 184,551 shares of Nurix Therapeutics worth $4.48M as of Q2 2026.
David Shaw sold 159,652 Nurix Therapeutics shares in Q2 2026, an estimated $2.72M.
Nurix Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2495 holding.
David Shaw first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 12 quarters since.
David Shaw's Nurix Therapeutics position peaked at $5.34M in Q1 2026.
210 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.